Takeda Pharmaceuticals Korea announced on the 17th that it has appointed Kim Mi-seung as the new head of its oncology division.
The new head, Kim Mi-seung, has over 20 years of experience in marketing, medical affairs, and academic sales in the domestic and international pharmaceutical and medical fields, focusing on oncology. He particularly led product strategies for treatments of blood cancers and solid tumors.
Until recently, he was in charge of the oncology division at Amgen Korea, where he led new product introductions and brand growth strategies. He has been recognized for contributing to the expansion of treatment accessibility through a patient-centered approach and data-driven decision-making capabilities.
After majoring in pharmacy at Chung-Ang University, Kim completed the Executive MBA program at Sungkyunkwan University and the Kelley School of Business at Indiana University in the United States. He also holds qualifications as a Board Certified Oncology Pharmacist (BCOP). He has worked as a clinical pharmacist at Samsung Medical Center and the National Cancer Center.
Takeda Pharmaceuticals Korea plans to further enhance the competitiveness of its oncology product line with the appointment of Kim.
Park Kwang-kyu, CEO of Takeda Pharmaceuticals Korea, noted that "the oncology division is a key strategic business for Takeda Pharmaceuticals Korea, playing a pivotal role in patient-centered innovation and expanding treatment accessibility," and added that "Kim Mi-seung, the new head, will lead the strengthening of the division's competitiveness and contribute to providing innovative treatment options to more patients."